Rus Eng
Main / Company's news / Rinsulin® became a leader at the market of gene-engineering insulins

29 December 2016

According to IMS, in the third quarter of 2016 Rinsulin® took the first place at the market of human gene-engineering insulins in terms of sales volume. In-kind share of GEROPHARM amounted to 23 %.

For the recent three years the volume of the market of human gene-engineering insulins has been stable. Except for GEROPHARM it is divided by foreign and Russian manufacturers: Lilly company, Novo Nordisk, Pharmstandard, Sanofi-Aventis, Medsintez, Bioton. The products are purchased with the money from the federal and regional budgets for preferential drug provision and hospital segment.

The share of GEROPHARM at the market of gene-engineering insulins has grown as the drug sales increased in some key regions – Moscow, Moscow Region, St. Petersburg, Kursk region, Khanty-Mansiysk Autonomous Region, Bashkortostan, etc. Cartridges became the largest part in the volume of procurement – the third quarter showed an absolute record – 195 thousand of packages.

Currently, a system of public procurement is being improved in most of the regions and the auctions are held in accordance with the law which guarantees an even access to the market for all participants. Today GEROPHARM-Bio is the only company manufacturing insulin as a full-cycle production complex within the Russian Federation. Maximum local content makes it possible to reduce the original cost of the lot by 40 % at the auction.

Today production capacity of the company can meet 30 % of the need in insulin within Russia. After commissioning of a new factory in Pushkin at 2018 the aggregate capacity of the current production site in Moscow Region and a new enterprise will be enough to meet the need of Russians in insulin to the full extent.

You are a health care professional?

Go up